2040, Concentrates and Pharmaceutical - Medical Cannabis Brief

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2040

Concentrates

Pharmaceutical

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Cannabis Law Report

NOVEMBER 12, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. ” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose. About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc.

Pharmaceutical

Pharmaceutical Clinical Trials Business Research and Development

Cannassure was granted a patent for an oral delivery method of cannabis and cannabinoids compositions by the Israel Patents Authority

Cannabis Law Report

AUGUST 9, 2021

The company’s innovative technology enables the provision of an exact amount of active ingredients through oral ingestion, using a high concentration of cannabinoids or medical cannabis extract in a homogeneous, uniform and stable formulation which can be administered in the form of oral capsules, syrups or buccal sprays.

Cannabinoids

Cannabinoids Pharmaceutical Treatment Patients

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Cannassure was granted a patent for an oral delivery method of cannabis and cannabinoids compositions by the Israel Patents Authority

Stay Connected